Transaction details
Akshay Vaishnaw, President of Research & Development at Scholar Rock Holding Corp (NASDAQ: SRRK), completed a sale of company common stock on April 16, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The filing shows 12,246 shares were disposed of at $49.5745 per share, producing proceeds of approximately $607,089.
The sale price was close to Scholar Rock’s 52-week high of $51.62 and comes amid a 55% gain in the stock over the past year.
Nature of the sale
The Form 4 specifies that the transaction was a "sell to cover" sale mandated by the issuer to satisfy tax withholding obligations arising from the vesting of restricted stock units (RSUs). As such, the filing indicates the transaction was not a discretionary sale by Mr. Vaishnaw.
The RSUs in question were granted on April 27, 2025, and vest on an annual schedule over four years, contingent on continued service with the company.
Post-transaction holdings
After the sell-to-cover transaction, Mr. Vaishnaw is reported to directly hold 630,542 shares of Scholar Rock. Those holdings are detailed in the filing as 58,521 shares of common stock, 122,021 restricted stock units subject to time-based vesting, and 450,000 restricted stock units subject to both performance- and time-based vesting conditions.
Valuation note
InvestingPro analysis cited in the filing materials indicates that Scholar Rock’s stock presently appears overvalued relative to its Fair Value estimate. The notice also states that InvestingPro provides deeper research and ProTips on SRRK and other U.S. equities for subscribers.
Regulatory and analyst context
Separately, Scholar Rock has resubmitted its Biologics License Application (BLA) for apitegromab to the U.S. Food and Drug Administration. The resubmission package now includes Catalent Indiana LLC, which is part of Novo Nordisk, and a second U.S.-based fill-finish facility. Company materials state the decision to resubmit was taken in coordination with the FDA following interactions in the first quarter of 2026.
The company previously received a Complete Response Letter in September 2025 stemming from observations made during an FDA inspection of Catalent Indiana; the filing notes those observations were not specific to apitegromab.
In response to the regulatory activity and related developments, several analysts adjusted their price targets while maintaining favorable ratings: Jefferies raised its target to $57, BofA Securities lifted its target to $58, both with Buy ratings, and Truist Securities reiterated a Buy rating with a $55 target after Roche halted development of a competing drug. The filings and analyst moves were presented as evidence of positive momentum for Scholar Rock.
What the filing does and does not show
The Form 4 makes clear that the April 16 transaction was executed to meet tax obligations associated with RSU vesting and was not portrayed as an intentional sale reflecting a change in the insider’s investment stance. The filing also establishes the structure and timing of the RSU awards and the current composition of Mr. Vaishnaw’s holdings.
Beyond those disclosures, the filing does not provide guidance on future insider transactions or on the attainment of the performance-based vesting conditions associated with 450,000 of the RSUs.
Note: This article presents the facts disclosed in regulatory filings and company announcements without adding interpretation beyond those statements.